Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 5Breast Neoplasms 4Vomiting 3Neoplasms 3Lymphoma, Non-Hodgkin 3Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Nausea 2Hodgkin Disease 2Hematologic Neoplasms 2Endometrial Neoplasms 2Burkitt Lymphoma 2Uterine Cervical Neoplasms 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Nausea and Vomiting 1Pathologic Complete Response 1Paraproteinemias 1Pain 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1NSCLC 1Mucositis 1Mastocytosis, Systemic 1

Interventions

Cyclophosphamide 65Rituximab 62fludarabine 40Etoposide 25Lenalidomide 19fludarabine phosphate 17Immunotherapy, Adoptive 17Doxorubicin 17Cytarabine 17Vincristine 15Magnetic Resonance Spectroscopy 14Prednisone 13pembrolizumab 11Specimen Handling 11Dexamethasone 10CT-P10 10Melphalan 9Carmustine 9Carboplatin 9Bortezomib 9Bendamustine Hydrochloride 9obinutuzumab 8ibrutinib 8Mycophenolic Acid 8Biopsy 8Radiotherapy 7Ifosfamide 7polatuzumab vedotin 6Whole-Body Irradiation 6Methotrexate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, B-Cell × Diphenhydramine × Clear all
NCT00482053 2018-05-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Stanford University

Phase 2 Terminated
3 enrolled 13 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡